Edition:
India

Sangamo Therapeutics Inc (SGMO.OQ)

SGMO.OQ on NASDAQ Stock Exchange Global Select Market

23.30USD
16 Feb 2018
Change (% chg)

$0.30 (+1.30%)
Prev Close
$23.00
Open
$23.15
Day's High
$23.70
Day's Low
$22.85
Volume
325,416
Avg. Vol
350,225
52-wk High
$23.70
52-wk Low
$3.65

Chart for

About

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company... (more)

Overall

Beta: 3.12
Market Cap(Mil.): $1,333.59
Shares Outstanding(Mil.): 83.61
Dividend: --
Yield (%): --

Financials

BRIEF-Sangamo Therapeutics Appoints Heather Turner As Senior Vice President

* SANGAMO THERAPEUTICS ANNOUNCES APPOINTMENT OF HEATHER D. TURNER AS SENIOR VICE PRESIDENT AND GENERAL COUNSEL Source text for Eikon: Further company coverage:

13 Feb 2018

BRIEF-Case Western Reserve, Sangamo Therapeutics get $11 Mln NIH Grant

* CASE WESTERN RESERVE AND SANGAMO THERAPEUTICS ANNOUNCE $11 MILLION NIH GRANT FOR STUDY OF GENE-EDITED T CELLS FOR VIRAL ERADICATION OF HIV

07 Feb 2018

Sangamo partners with Pfizer to develop gene therapy for ALS

Sangamo Therapeutics Inc and Pfizer Inc said on Wednesday they would work together to develop a gene therapy to treat ALS, a disease that affects nerve cells in the brain and the spinal cord.

03 Jan 2018

Sangamo partners with Pfizer to develop gene therapy for ALS

Sangamo Therapeutics Inc and Pfizer Inc said on Wednesday they would work together to develop a gene therapy to treat ALS, a disease that affects nerve cells in the brain and the spinal cord.

03 Jan 2018

Sangamo partners with Pfizer to develop gene therapy for ALS

Jan 3 Sangamo Therapeutics Inc and Pfizer Inc said on Wednesday they would work together to develop a gene therapy to treat ALS, a disease that affects nerve cells in the brain and the spinal cord.

03 Jan 2018

BRIEF-Sangamo And Pfizer Announce Collaboration For Development Of Zinc Finger Protein Gene Therapy For Als

* SANGAMO AND PFIZER ANNOUNCE COLLABORATION FOR DEVELOPMENT OF ZINC FINGER PROTEIN GENE THERAPY FOR ALS

03 Jan 2018

BRIEF-Sangamo Therapeutics posts Q3 loss per share $0.15

* Sangamo Therapeutics reports third quarter 2017 financial results

10 Nov 2017

BRIEF-Sangamo and Bioverativ announce FDA acceptance of IND application for ST-400

* Sangamo and Bioverativ announce FDA acceptance of IND application for ST-400 -- a gene-edited cell therapy candidate -- to treat beta-thalassemia

02 Oct 2017

Competitors

  Price Chg
Novo Nordisk A/S (NOVOb.CO) kr.313.45 +8.25
Pfizer Inc. (PFE.N) $36.26 +0.55
Novartis AG (NOVN.S) CHF80.80 +1.18
Merck & Co., Inc. (MRK.N) $56.29 +0.30
Roche Holding Ltd. (ROG.S) CHF225.50 +2.10
Roche Holding Ltd. (RO.S) CHF230.20 +2.60
Bayer AG (BAYGn.DE) €98.54 +1.15
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €64.50 +1.00
GlaxoSmithKline plc (GSK.L) 1,318.60 +18.20

Earnings vs. Estimates